Insider Selling: LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $16,014,000.00 in Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George Lemaitre sold 150,000 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the sale, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock opened at $106.41 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $115.33. The company has a fifty day moving average price of $88.39 and a two-hundred day moving average price of $88.60. The company has a market cap of $2.42 billion, a PE ratio of 42.39, a P/E/G ratio of 3.11 and a beta of 0.66.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. During the same period in the prior year, the firm earned $0.49 EPS. The business’s quarterly revenue was up 15.7% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 26th. Investors of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LMAT. Vest Financial LLC raised its position in shares of LeMaitre Vascular by 60.0% during the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier’s stock worth $4,925,000 after purchasing an additional 21,102 shares during the period. SG Americas Securities LLC purchased a new position in LeMaitre Vascular in the 3rd quarter worth about $1,101,000. First Trust Advisors LP raised its holdings in LeMaitre Vascular by 52.7% during the 2nd quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after buying an additional 211,280 shares during the period. Envestnet Asset Management Inc. raised its holdings in LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after buying an additional 19,447 shares during the period. Finally, Congress Asset Management Co. lifted its stake in LeMaitre Vascular by 2.7% during the third quarter. Congress Asset Management Co. now owns 692,266 shares of the medical instruments supplier’s stock valued at $60,580,000 after buying an additional 18,298 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the topic of several research analyst reports. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Roth Mkm reiterated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Citizens Jmp boosted their target price on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Hold” and an average target price of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.